Southern Crop

Southern Crop

Skin patch to treat peanut allergy shows benefit in children; NIH-funded study suggests patch is safe, convenient mode of treatment

Peanut Allergy Treatment – A Wearable Patch that “… delivers small amounts of peanut protein through the skin shows promise for treating children and young adults with peanut allergy, with greater benefits for younger children …”, according to one-year results from an ongoing clinical trial sponsored by the NIH National Institute of Allergy and Infectious Diseases (NIAID) and published online on October 26 in the Journal of Allergy and Clinical Immunology – The treatment, called epicutaneous immunotherapy or EPIT, was “… safe and well-tolerated, and nearly all participants used the skin patch daily as directed …” – The study was conducted by the NIAID-funded Consortium of Food Allergy Research and the patches were “… developed and provided by the biopharmaceutical company DBV Technologies under the trade name Viaskin. Each day, study participants applied a new patch to their arm or between their shoulder blades … After one year, researchers assessed each participant’s ability to consume at least 10 times more peanut protein than he or she was able to consume before starting EPIT … None reported serious reactions to the patch, although most experienced mild skin reactions, such as itching or rash, at the site of patch application …”

Document Title: The title of the October 26, 2016 NIH NIAID News Release is “Skin patch to treat peanut allergy shows benefit in children; NIH-funded study suggests patch is safe, convenient mode of treatment”

Organization: NIH NIAID Press Office

Source: October 26, 2016 NIH News Release

Web site: The October 26, 2016 NIH News Release is posted at
http://www.nih.gov/news-events/news-releases/skin-patch-treat-peanut-allergy-shows-benefit-children

The research article published online on October 26, 2016 in the Journal of Allergy and Clinical Immunology, titled “Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults”, is posted at
http://www.jacionline.org/article/S0091-6749(16)30966-6/fulltext

Additional information about the Clinical Trial is posted at
http://clinicaltrials.gov/ct2/show/NCT01904604

Information about the Consortium of Food Allergy Research (CoFAR) is available at
http://www.cofargroup.org/

Related Articles

EPA says its recently completed analysis of the potential human health risks of the pesticide chlorpyrifos, including exposures through drinking water, does not alter its plan to ban use of the substance on food, though the agency is seeking public input on its revised scientific analysis in advance of a[…]

Read More »
glyphosate (2)

Competing Claims Over Glyphosate’s Risks Pose Challenge For EPA SAP

Pesticide industry officials and environmentalists are waging competing claims over the public health risks from the world’s most commonly-used herbicide glyphosate in comments to a delayed EPA Science Advisory Panel (SAP), highlighting the challenge the panel faces in its pending work to assess evidence on the substance’s risks. Read more

Read More »

Leave a Reply

Your email address will not be published. Required fields are marked *